---
title: "First Tracks Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295709002.md"
datetime: "2026-08-12T20:57:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295709002.md)
  - [en](https://longbridge.com/en/news/295709002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295709002.md)
---

# First Tracks Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.95.

EBIT: As of FY2026 Q2, the actual value is USD -34.94 M.

The provided reference indicates that First Tracks Biotherapeutics, Inc. issued a press release on August 12, 2026, detailing its financial results for the three and six months ended June 30, 2026. However, the actual financial and operational metrics, cash flow details, unique company-specific indicators, or any forward-looking outlook/guidance are not included within the text provided in this specific reference document.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)

## Related News & Research

- [Eidesvik Offshore to present Q2 2026 results in digital briefing](https://longbridge.com/en/news/295931470.md)
- [Vital Farms amends 8-K to add missing Item 5.03 in EDGAR header](https://longbridge.com/en/news/296122466.md)
- [Xylem sets quarterly distribution at R$ 0.75 per unit for 3Q 2026](https://longbridge.com/en/news/296117630.md)
- [Investors House to release H1 2026 results](https://longbridge.com/en/news/295920631.md)
- [Canopy Growth publishes fiscal 2026 annual report to shareholders](https://longbridge.com/en/news/296098371.md)